MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route
Author:
Affiliation:
1. Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun City, China
Funder
Science and Technology Development Program of Jilin province
Publisher
Informa UK Limited
Subject
Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology
Link
https://www.tandfonline.com/doi/pdf/10.1080/21655979.2021.1939577
Reference32 articles.
1. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
2. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
3. Fractionated Scheme of Oral Vinorelbine as Single-Agent Therapy or in Combination With Cisplatin Concomitantly With Thoracic Radiotherapy in Stage III Non–Small-Cell Lung Cancer: Dose-Escalation Phase I Trial
4. Cisplatin: The first metal based anticancer drug
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer;Frontiers in Oncology;2023-12-19
2. A comprehension of signaling pathways and drug resistance; an insight into the correlation between microRNAs and cancer;Pathology - Research and Practice;2023-11
3. Circ_0102231 inactivates the PI3K/AKT signaling pathway by regulating the miR‐635/NOVA2 pathway to promote the progression of non‐small cell lung cancer;Thoracic Cancer;2023-10-20
4. MicroRNA‐577/EIF5A2 axis suppressed the proliferation of DDP‐resistant nasopharyngeal carcinoma cells by blocking TGF‐β signaling pathway;Chemical Biology & Drug Design;2023-07-27
5. MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3